EATG » Access

Access

PrEP drug patent overturned in UK – NAT respond

September 18, 2018: The High Court has today overturned Gilead's patent extension on Truvada, the HIV drug also used in PrEP. Deborah Gold, chief executive of NAT (National AIDS Trust)…

HIV drugs cost $75 in Africa, $39,000 in the US. Does it matter?

In the United States, pharmaceutical companies have built a system which supports high costs for HIV drugs. But that may be starting to change. Read the full article here.  

EPO upholds Gilead patent on hep C medicines, but in amended form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained…

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection…

Drug price cut will expand access to a key treatment for HIV coinfections

GENEVA, 12 September 2018 – Unitaid welcomes the announcement by Gilead Sciences, Inc. that it will cut the price of the WHO-recommended drug AmBisome® to treat cryptococcal meningitis, an opportunistic infection…

Groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

Gilead’s price gouging for sofosbuvir blocks millions of people from getting treatment NEW YORK/MUNICH/PARIS, SEPTEMBER 11, 2018—This week in Munich, the European Patent Office (EPO) will hear a legal challenge…

New confidential text shows draft deal on UN TB Declaration

A newly agreed draft text of the United Nations political declaration on tuberculosis was released to governments today, affirming the use of flexibilities in international trade rules on intellectual property,…

UN TB negotiations: What is at stake?

With negotiations over the final language of a United Nations high level declaration on ending tuberculosis still ongoing, the stakes are high as different TB stakeholders await the outcome. The…

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound, opening life-saving hepatitis C treatment access for millions I-MAK’s successful patent challenge against Gilead cracks open…

Open letter: UN General Assembly High Level Meeting on the fight against Tuberculosis

Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter: 'As negotiations on the final declaration are now being…

1 2 3 37